Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years.
Luiz Sérgio Fernandes de CarvalhoAlessandra M CamposAndrei Carvalho SpositoPublished in: Diabetes care (2017)
In the short term, PCSK9i therapy favors a small but significant increase in plasma glycemia and HbA1c.